Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCSF Bain Capital Specialty Finance	$16.21 +1.0%	$15.64	$11.06 ▼ $16.80	N/A	1.14	256,886 shs	166,330 shs
CO Global Cord Blood	$1.25	$1.51	$2.03 ▼ $5.50	$151.94M	0.16	216,519 shs	1,788 shs
GSAH GS Acquisition Holdings Corp II	$10.54	$10.23	$9.83 ▼ $16.66	$988.13M	-0.11	2.05 million shs	2.63 million shs
HYAC Haymaker Acquisition Corp. III	$10.46 +0.1%	$9.77	$8.92 ▼ $10.52	$309.09M	N/A	26,058 shs	9,173 shs
IMVT Immunovant	$29.37 +2.2%	$32.84	$15.39 ▼ $45.58	$4.27B	0.65	1.22 million shs	462,673 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCSF Bain Capital Specialty Finance	+1.81%	+2.98%	+1.23%	+4.73%	+37.25%
CO Global Cord Blood	0.00%	0.00%	-16.67%	0.00%	-58.16%
GSAH GS Acquisition Holdings Corp II	0.00%	0.00%	0.00%	0.00%	0.00%
HYAC Haymaker Acquisition Corp. III	0.00%	0.00%	+0.58%	+1.36%	+15.85%
IMVT Immunovant	+1.84%	-5.68%	-10.75%	-26.98%	+85.42%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCSF Bain Capital Specialty Finance	0.6831 of 5 stars	1.0	5.0	1.7	0.0	1.2	0.0	1.3
CO Global Cord Blood	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GSAH GS Acquisition Holdings Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HYAC Haymaker Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	2.5921 of 5 stars	4.5	2.0	0.0	0.0	2.4	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCSF Bain Capital Specialty Finance	2.00	Hold	$14.75	-9.01% Downside
CO Global Cord Blood	N/A	N/A	N/A	N/A
GSAH GS Acquisition Holdings Corp II	N/A	N/A	N/A	N/A
HYAC Haymaker Acquisition Corp. III	N/A	N/A	N/A	N/A
IMVT Immunovant	3.00	Buy	$48.00	63.43% Upside

Current Analyst Ratings

Latest BCSF, GSAH, IMVT, CO, and HYAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2024	IMVT Immunovant	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/25/2024	IMVT Immunovant	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$48.00
3/13/2024	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
2/20/2024	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00
2/15/2024	IMVT Immunovant	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
1/29/2024	BCSF Bain Capital Specialty Finance	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$13.75 ➝ $14.50

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCSF Bain Capital Specialty Finance	$297.79M	N/A	N/A	N/A	N/A	N/A
CO Global Cord Blood	$1.24B	0.12	$0.30 per share	4.19	$6.34 per share	0.20
GSAH GS Acquisition Holdings Corp II	$70K	14,116.07	N/A	N/A	$6.96 per share	1.51
HYAC Haymaker Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.78 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCSF Bain Capital Specialty Finance	$123.38M	$1.90	8.53	8.31	N/A	41.43%	12.54%	5.49%	5/14/2024 (Estimated)
CO Global Cord Blood	$79.04M	$0.64	1.95	∞	N/A	N/A	N/A	N/A	N/A
GSAH GS Acquisition Holdings Corp II	-$45.26M	N/A	0.00	∞	N/A	-49,263.32%	-9.11%	-5.88%	N/A
HYAC Haymaker Acquisition Corp. III	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	-$210.96M	-$1.84	N/A	N/A	N/A	N/A	-57.97%	-52.47%	5/27/2024 (Estimated)

Latest BCSF, GSAH, IMVT, CO, and HYAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/27/2024	Q4 2023	BCSF Bain Capital Specialty Finance	$0.54	$0.54	N/A	$0.60	N/A	$74.95 million
2/12/2024	12/31/2023	IMVT Immunovant	-$0.43	-$0.36	+$0.07	-$0.36	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCSF Bain Capital Specialty Finance	$1.68	10.36%	+3.82%	88.42%	2 Years
CO Global Cord Blood	$0.08	6.40%	N/A	12.50%	N/A
GSAH GS Acquisition Holdings Corp II	N/A	N/A	N/A	N/A	N/A
HYAC Haymaker Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A

Latest BCSF, GSAH, IMVT, CO, and HYAC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/27/2024	BCSF Bain Capital Specialty Finance	Quarterly	$0.45	11.58%	3/27/2024	3/28/2024	4/30/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCSF Bain Capital Specialty Finance	1.11	2.18	2.18
CO Global Cord Blood	N/A	N/A	N/A
GSAH GS Acquisition Holdings Corp II	N/A	0.02	0.02
HYAC Haymaker Acquisition Corp. III	N/A	N/A	N/A
IMVT Immunovant	N/A	22.14	22.14

Ownership

Institutional Ownership

Company	Institutional Ownership
BCSF Bain Capital Specialty Finance	N/A
CO Global Cord Blood	N/A
GSAH GS Acquisition Holdings Corp II	49.06%
HYAC Haymaker Acquisition Corp. III	71.07%
IMVT Immunovant	47.08%

Insider Ownership

Company	Insider Ownership
BCSF Bain Capital Specialty Finance	0.55%
CO Global Cord Blood	0.50%
GSAH GS Acquisition Holdings Corp II	N/A
HYAC Haymaker Acquisition Corp. III	N/A
IMVT Immunovant	4.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BCSF Bain Capital Specialty Finance	1,000	N/A	N/A	Optionable
CO Global Cord Blood	1,202	121.55 million	N/A	No Data
GSAH GS Acquisition Holdings Corp II	2	93.75 million	N/A	Not Optionable
HYAC Haymaker Acquisition Corp. III	4	29.55 million	N/A	Not Optionable
IMVT Immunovant	164	145.29 million	138.32 million	Optionable

BCSF, GSAH, IMVT, CO, and HYAC Headlines

Source	Headline
	Allspring Global Investments Holdings LLC Acquires 36,659 Shares of Immunovant, Inc. (NASDAQ:IMVT) marketbeat.com - April 23 at 4:33 AM
	Buy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy Confidence markets.businessinsider.com - April 22 at 5:52 PM
	Here's Why You Should Add Immunovant (IMVT) to Your Portfolio zacks.com - April 22 at 12:56 PM
	Julia G. Butchko Sells 10,115 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock insidertrades.com - April 21 at 6:28 AM
	Eva Renee Barnett Sells 12,253 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock americanbankingnews.com - April 21 at 5:44 AM
	Peter Salzmann Sells 34,079 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock americanbankingnews.com - April 21 at 4:32 AM
	Immunovant CFO sells shares worth over $350k investing.com - April 20 at 7:50 PM
	Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $293,941.90 in Stock marketbeat.com - April 19 at 6:44 PM
	What Makes Immunovant (IMVT) a New Buy Stock zacks.com - April 17 at 1:01 PM
	Immunovant (NASDAQ:IMVT) Trading Down 3.6% marketbeat.com - April 17 at 11:58 AM
	Immunovant, Inc. (IMVT) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - April 16 at 11:45 PM
	WCM Investment Management LLC Takes $4.55 Million Position in Immunovant, Inc. (NASDAQ:IMVT) marketbeat.com - April 15 at 7:20 AM
	Immunovant is Now Oversold (IMVT) nasdaq.com - April 15 at 12:05 AM
	Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by Brokerages americanbankingnews.com - April 13 at 4:50 AM
	Immunovant CEO sells over $149,000 in company stock investing.com - April 12 at 7:12 PM
	Immunovant, Inc. (NASDAQ:IMVT) Expected to Post Q1 2026 Earnings of ($0.49) Per Share marketbeat.com - April 11 at 7:58 AM
	Immunovant, Inc. (NASDAQ:IMVT) Insider Julia G. Butchko Sells 1,053 Shares insidertrades.com - April 11 at 6:48 AM
	Julia G. Butchko Sells 1,053 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock marketbeat.com - April 10 at 6:42 PM
	Immunovant (NASDAQ:IMVT) Stock Price Down 2.8% marketbeat.com - April 8 at 11:59 AM
	Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade) seekingalpha.com - April 4 at 2:12 AM
	Immunovant, Inc. (NASDAQ:IMVT) Sees Significant Increase in Short Interest marketbeat.com - April 2 at 6:55 AM
	121,268 Shares in Immunovant, Inc. (NASDAQ:IMVT) Acquired by Assenagon Asset Management S.A. marketbeat.com - April 1 at 4:43 AM
	SG Americas Securities LLC Reduces Stake in Immunovant, Inc. (NASDAQ:IMVT) marketbeat.com - March 30 at 4:25 AM
	Wellington Management Group LLP Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) marketbeat.com - March 26 at 4:16 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
3 Cheap Stocks That Shouldn’t Be Cheap for Long
March 26, 2024 9:49 AM
View 3 Cheap Stocks That Shouldn’t Be Cheap for Long

All Headlines

Company Descriptions

Bain Capital Specialty Finance

NYSE:BCSF

Bain Capital Specialty Finance, Inc. is business development company specializing in direct loans to middle-market companies. The fund seeks to invest in senior investments with a first or second lien on collateral, senior first lien, stretch senior, senior second lien, unitranche, mezzanine debt, junior securities, other junior investments, and secondary purchases of assets or portfolios that primarily consist of middle-market corporate debt. It typically invests in companies with EBITDA between $10 million and $150 million.

Global Cord Blood

NYSE:CO

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

GS Acquisition Holdings Corp II

NYSE:GSAH

GS Acquisition Holdings Corp II does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar transaction with one or more businesses. It focuses on seeking opportunities in diversified industrial, healthcare, technology, media and telecom, and alternatives asset management sectors. The company was incorporated in 2018 and is based in New York, New York.

Haymaker Acquisition Corp. III

NASDAQ:HYAC

Haymaker Acquisition Corp. III does not have any significant operations. It intends to acquire and operate a business in the consumer and consumer-related products. The company was incorporated in 2020 and is based in New York, New York.

Immunovant

NASDAQ:IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial